SHOC2 M173I disrupts the SHOC2:MRAS:PP1 complex

Stable Identifier
R-HSA-9660536
Type
Reaction [transition]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
A loss-of-function mutation in SHOC2 has been identified in a patient with a Noonan-related syndrome (Hannig et al, 2014). SHOC2 M173I has impaired ability to interact with PPP1CC and reduces the MRAS-SHOC2-PP1-dependent dephosphorylation of RAF, which is required for RAF pathway activation (Rodriguez-Viciano et al, 2006; Hannig et al, 2014). How both loss and gain-of-function SHOC2 mutants can contribute to RAF pathway activation remains to be elucidated.
Literature References
PubMed ID Title Journal Year
25137548 A Novel SHOC2 Variant in Rasopathy

Hannig, V, Galperin, E, Phillips, JA, Jeoung, M, Jang, ER

Hum. Mutat. 2014
16630891 A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity

McCormick, F, Fried, M, Burlingame, A, Oses-Prieto, J, Rodriguez-Viciana, P

Mol. Cell 2006
Participants
Participates
Catalyst Activity

protein serine/threonine phosphatase activity of SHOC2 M173I:MRAS:PP1 [plasma membrane]

Normal reaction
Functional status

Loss of function of SHOC2 M173I:MRAS:PP1 [plasma membrane]

Status
Disease
Name Identifier Synonyms
Noonan syndrome DOID:3490 Turner's phenotype, karyotype normal (disorder)
Authored
Reviewed
Created
Cite Us!